New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
11:08 EDTTROVTrovagene says diagnostic platform demonstrates ability to monitor mutations
Clinical study results presented at the American Association for Cancer Research Annual Meeting demonstrate the ability of Trovagene's molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients, the company said. Of the 33 patients enrolled in the study, Trovagene's BRAF V600E oncogene mutation assay was able to identify the mutation in 29 patients, or 88%, at any time point during the study, demonstrating a high level of concordance with tissue biopsy. In addition, 25 of the 33 patients, or 76%, were positively identified for the mutation with their first urine sample. Mark Erlander, Ph.D., chief scientific officer of Trovagene, stated, "The concordance shown between our platform and tissue biopsy in this study are encouraging, especially when we consider that different patients will show response to treatments at different times."
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:52 EDTTROVTrovagene price target raised to $13 from $10 at Maxim
Maxim raised Buy rated Trovagene's price target to $13 following the presentation at the 2015 European Lung Cancer Conference demonstrating high clinical utility of its Precision Cancer platform.
April 17, 2015
12:21 EDTTROVOn The Fly: Top stock stories at midday
Subscribe for More Information
10:31 EDTTROVTrovagene says ctDNA assay outperformed tissue biopsy in clinical study
Trovagene announced that clinical data presented at the 2015 European Lung Cancer Conference demonstrate that its urine-based Precision Cancer Monitoring platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland. In an interim analysis of 34 patients from an ongoing clinical study, Trovagene's PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The company's urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. Trovagene's PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use